NDAORALTABLET
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TRIBENZOR (olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide) by Pfizer is regulation. Approved for hypertension, to lower blood pressure. First approved in 2010.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIBENZOR is a fixed-dose combination oral tablet containing olmesartan medoxomil (ARB), amlodipine besylate (calcium channel blocker), and hydrochlorothiazide (thiazide diuretic) approved in 2010 for hypertension management. It works through three complementary mechanisms: blocking angiotensin II receptors, inhibiting calcium influx into vascular smooth muscle, and promoting sodium/chloride excretion to reduce blood pressure.
$2.0MPart D
LOE ApproachingDeclining commercial activity with approaching loss of exclusivity signals transition from growth to managed decline, requiring focused retention and generics-transition strategies.
Mechanism of Action
regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; olmesartan medoxomil blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle, adrenal and renal cells; and…
Worked on TRIBENZOR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.